Risk factors
MoonLake Immunotherapeutics (MLTX) risk factors
Item 1A of every MoonLake Immunotherapeutics 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors69 risks15 new6 dropped16 reworded
MoonLake added financing and compliance risks, updated clinical trial timelines for SLK, and disclosed ongoing securities class action litigation.
Filed Feb 25, 2026 - FY2024 10-K risk factors60 risks
MoonLake has no approved products and relies entirely on the success of its lead candidate SLK for inflammatory conditions. The company depends heavily on external contract manufacturers for SLK supply and third-party licenses for intellectual property. Operations have generated ongoing losses, requiring future capital raises and patient enrollment in clinical trials to achieve commercial viability.
Filed Feb 26, 2025